Five things for pharma marketers to know: Tuesday, July 17, 2018

Share this content:

Johnson & Johnson's second-quarter revenue, up 10.6% from the previous year, beat analysts' expectations, as did its earnings in the period. Areas of growth included pharmaceutical and medical devices. Its consumer division fell short of analysts' predictions. (CNBC)


AbbVie has signed a U.S. license deal with Mylan for its proposed biosimilar to Humira. The deal will help AbbVie maintain control of the market through 2023, when Mylan can launch its Humira biosimilar. (Reuters)


Roche's second Phase III trial for its new flu drug met primary endpoints. The single-dose treatment, an alternative to Tamiflu, sped up the reduction of symptoms in the latest trial. The flu drug will be reviewed at the end of this year with a potential launch in early winter. (Endpoints)


Huntsworth has acquired Giant Creative Strategy for $72 million. Giant founders Steven Gold, CEO, and Adam Gellion, president, will hold on to nearly 10% of ownership. The deal follows Huntsworth's acquisition of the Creative Engagement Group. (MM&M)


FDA Commissioner Scott Gottlieb shared a plan for making more prescription drugs available over the counter. The process would use digital health technologies to help patients self-select a treatment and could lower healthcare costs for patients with common conditions or chronic conditions. (FDA)

Share this content:
Scroll down to see the next article